The critical role of industry in the PMS and master data
-
Hanna Saari
Master data is integral to the EMA’s four data management services: substance, product, organisation and referential (SPOR). The Product Management Service (PMS) is a central plank in the SPOR program and will be used as a trusted source of product information.
EMA is proceeding with its PMS roadmap,2 which most urgently includes providing data to the European Shortages Monitoring Platform (ESMP) and electronic Application Forms (eAFs). Industry will need to work with the agency to submit their data to the PMS and to check and cleanse that data.
Data cleansing needed
Once that data is checked and cleansed, the next step will be to enrich the dataset with information about the manufacturer and their role (for example, are they responsible for producing the active pharmaceutical ingredient or formulating the tablets?), as well as inclusion of the structured packaging data. Manufacturing information will be required for the ESMP to ensure greater transparency over the supply chains.
EMA has extended the deadlines for enrichment of the data for products on the critical medicines list until June 2026 and for other products until December 2026 (manufacturer data) or June 2027 (structured packaging data); however, companies need to act urgently to fulfill these requirements.
There is still a lot to do before enrichment can happen. An important starting point will be to integrate data processes into regulatory processes. Have a clear data governance process in place and make sure there is ownership of the data. And implement proper regulatory information management.
The agency is developing tools to support industry with the transition to PMS. Now it is up to industry to ensure it provides the resources and commitment needed to achieve the goal of a shared repository of trusted product master data.
About the author:
Disclaimer:
The opinions expressed in this blog are solely those of the author. This material may include certain marketing statements and does not constitute legal advice. Cencora, Inc., strongly encourages readers to review all relevant information on the topics addressed and to rely on their own experiences and expertise when making decisions related thereto.
Ta kontakt med teamet vårt
Sources:
1. Medicinal Product master data for better regulation and better health, HMA and EMA, May 2025. https://www.ema.europa.eu/en/documents/other/medicinal-product-master-data-better-regulation-better-health-network-data-steering-group-ndsg-recommendations-human-product-master-data-implementation-data-management_en.pdf
2. Product Management Service roadmap, EMA. https://www.ema.europa.eu/en/documents/other/product-management-service-pms-roadmap_en.pdf
Cencora.com tilbyr automatiserte oversettelser for å hjelpe deg med å lese nettstedet på andre språk enn engelsk. Mye arbeid er lagt ned i disse oversettelsene for å gjøre dem nøyaktige, men ingen automatisert oversettelse er perfekt, og slike oversettelser er heller ikke ment å erstatte menneskelige oversettere. Disse oversettelsene leveres som en tjeneste til brukere av Cencora.com og leveres «som de er». Det gis ingen garanti av noe slag, verken uttrykt eller underforstått, med hensyn til nøyaktigheten, påliteligheten eller riktigheten av noen av disse oversettelsene som er gjort fra engelsk til andre språk. Det kan hende at noen typer innhold (som bilder, videoer, Flash osv.) er unøyaktig oversatt på grunn av begrensningene i oversettelsesprogramvaren.
Eventuelle avvik eller forskjeller som oppstår ved oversettelse av dette innholdet fra engelsk til et annet språk, er ikke bindende og har ingen juridisk virkning for samsvar, håndhevelse eller andre formål. Kontakt oss dersom du oppdager feil. Se den engelske versjonen av siden dersom du er i tvil om hvorvidt informasjonen i disse oversettelsene er nøyaktig.